

Marwan G. Fakih, MD

Professor and Section Head, GI Oncology
Department of Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
1500 E Duarte Road
Duarte, CA 91010
Tel: 626-256-4673 extension 63087
e-mail: mfakih@coh.org



Education and Training

American University of Beirut, Lebanon (BS) Biology	06/1988
American University of Beirut, Lebanon (MD) Medicine	06/1992
Internship & Residency, Wayne State University, Detroit, MI, Internal Medicine	08/1992-06/1995
Fellowship, University of Pittsburgh Medical Center Pittsburgh, PA, Hematology & Oncology	08/1998-06/2001

Certification and Licensure

1993	Lebanon Medical License
1994	Michigan Medical License #4301059972
1995	American Board of Internal Medicine Certification
1998	Pennsylvania Medical License #MD064159L
2001	American Board of Medical Oncology Certification
2002	New York Medical License #224776-1
2011	American Board of Medical Oncology Recertification
2012	The Medical Board of California License C55385

Academic, Administrative and Clinical Appointments

08/1992-06/1995	Internship & Residency, Wayne State University, Detroit, MI, Internal Medicine
07/1995-09/1995	Staff Physician, Medical Centers, West Branch/ Alger (MI) [Acquired by McLaren Medical Center in September 1995]
10/1995-02/1998	Staff Physician, Department of Internal Medicine, McLaren Medical Center, Flint, MI
07/1998-06/2001	Fellowship, University of Pittsburgh Medical Center Pittsburgh, PA, Hematology & Oncology
07/2001-06/2002	Assistant Professor of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
07/2002-03/2010	Assistant Professor of Medicine, University at Buffalo, Buffalo, NY
03/2006 -08/2011	Assistant Professor, Graduate Faculty, Dept. of Pharm & Therapeutics, Roswell Park Cancer Institute, Buffalo, NY

10/2006-08/2011	Associate Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY
03/2007 -08/2011	Gastrointestinal Oncology Section Leader, Roswell Park Cancer Institute, Buffalo, NY
12/2008 -08/2011	Leader, GI Disease Site Research Group, Roswell Park Cancer Institute, Buffalo, NY
11/2008-06/2011	Chair, Scientific Review Committee, Roswell Park Cancer Institute, Buffalo, NY
12/2008 -08/2011	Medical Director, Roswell Park Cancer Inst. Clinical Network (outreach), Buffalo, NY
03/2010-08/2011	Associate Professor of Medicine (tenure track), University at Buffalo, Buffalo, NY
09/2011-10/2012	Professor of Medicine, University of Michigan, Ann Arbor, MI
09/2011-10/2012	Co-Director GI Oncology Program, University of Michigan, Ann Arbor, MI
11/2012- current	Professor, City of Hope Comprehensive Cancer Center, Duarte, CA
11/2012- current	Section Head, GI Medical Oncology Section, City of Hope Comprehensive Medical Center, Duarte, CA
7/2014-10/2016	City of Hope Site Director of Hem-Onc Fellowship
1/2015-12/31/2015	Interim Chair, Department of Medical Oncology & Therapeutics Research, City of Hope
10/2015-current	Director of Clinical Research Network, City of Hope
01/2017-current	NCCN Board of Directors

Grants

A. Previous Grant Funding

1. American Cancer Society #MRSG-04-270-01 CCE
Calcitriol as an Antitumor Agent in Advanced Colon Cancer
PI: Marwan Fakih, MD
07/01/2004-06/30/2009
Role: Principal Investigator
Funding: \$ 712,000
2. CALGB/CCOP #CA37447-26
A Pilot Prevention Study of Low and High Dose Vitamin D3 with Pharmacokinetic and Pharmacodynamic Correlates in Patients with Resected Colon Cancer
PI: Marwan Fakih, MD
06/01/2006-05/31/2009
Role: Principal Investigator
Funding: \$75,000
3. Alliance Foundation – Roswell Park Cancer Institute # n/a
Identification of 24-hydroxylase single nucleotide polymorphisms and splicing variants that modulate vitamin D oxidative metabolism and serum pharmacokinetics in patients with colorectal cancer on cholecalciferol therapy.
PI: Josephia Muindi, MD, PhD

01/01/2007-01/31/2009
Role: Co-Investigator
Funding: \$ 50,000

4. NCI/NIH #R21-7789843
Vitamin D3 Metabolism and Colorectal Cancer: Correlating Phenotype to Genotype
PI: Josephia Muindi, MD, PhD
12/01/2009-11/30/2011
Role: Co-Investigator and Clinical Principal Investigator
Funding: \$509,014

Investigator-Initiated Studies (Completed)

- | | |
|--|---------|
| 1. (RP 02-09) Aventis Supported – (\$144,000)
A Phase I and Pharmacokinetic Study of Docetaxel in Combination
with Capecitabine and Cisplatin in Solid Tumors. (2004) – PI (FAKIH) | 2002-4 |
| 2. (I03003) (RPCI-supported)
A Phase I and Pharmacokinetic Study of Irinotecan in
Combination with Selenomethionine in Advanced Solid Tumors - PI (FAKIH) | 2003-5 |
| 3. (I17403) Astra Zeneca-supported (\$170,000)
A Phase I/II Study of Capecitabine (XELODA®, Roche) Plus
Oxaliplatin (ELOXATIN®, Sanofi) Plus ZD1839 (IRESSA®)
in the Treatment of Metastatic Colorectal Cancer - PI (FAKIH) | 2004-5 |
| 4. (RP 02-07) Supported by RO1- CA67267-14
A Phase I Study of Intravenous (IV) Calcitriol in Combination
with ZD 1839 (Iressa) in Refractory Solid Tumors – PI (FAKIH) | 2003-6 |
| 5. (I22204) Genentech-supported (\$200,000)
A phase II study of capecitabine and bevacizumab in the first line
Treatment of Metastatic Colorectal Cancer in Patients > 70 | 2004-7 |
| 6. (I10803) Sanofi-supported (\$220,000)
A Phase I/II Study of Weekly Intravenous Oxaliplatin in Combination
with Oral Daily Capecitabine and Radiation Therapy in the
Neoadjuvant Treatment of Rectal Cancer – PI (FAKIH) | 2004-7 |
| 7. (I32804) RPCI-supported
A Phase I and Pharmacokinetic Study of Selenomethionine
and Fixed Dose Irinotecan in Advanced Solid Tumors – PI (FAKIH) | 2005-7 |
| 8. (I22204) Genentech-supported (\$200,000)
A Phase II Study of Capecitabine and Bevacizumab in Elderly Patients with
Metastatic Colorectal Cancer Standard Therapy. – PI (Fakih) | 2004 -8 |
| 9. (I55305) A phase I study of SAHA and 5-FU in advanced | 2007-9 |

Solid tumors (*Partly supported by CTEP*) – PI (FAKIH)

10. Merck-supported (\$488,000) – PI (FAKIH) 2009-11
A randomized phase II Study of 5-FU/LV with two dose-levels of vorinostat in patients with refractory advanced colorectal cancer (PI- FAKIH)
11. BMS-supported (\$250,000) – PI (FAKIH) 2009-11
A phase II of high dose cetuximab in combination with irinotecan in patients with KRAS-wild type tumor who failed standard dose cetuximab (PI- FAKIH)
12. A phase I study of MEK162 plus FOLFOX in chemotherapy resistant metastatic colorectal cancer (2014- PI, Fakih; Grant Support from Novartis \$370,000)

Ongoing Support (Investigator Initiated Studies)

1. A phase I/II Study of Nintedanib in Refractory Metastatic Colorectal Cancer (2015-Co –PI Fakih; NCCN grant: \$73, 949)
2. A pilot trial of radioembolization followed by durvalumab and tremelimumab in patients with liver predominant metastatic colorectal cancer with MSS (2017- PI Fakih, Grant Support from AZ for \$350,000)
3. A phase I trial of trametinib plus TAS-102 in patients with RAS-mutant, PIK3 wild-type, and PTEN wild-type refractory metastatic colorectal cancer (2017- PI Fakih, Grant Support from Novartis)

Honors and Awards

- | | |
|-----------|---|
| 1987-1990 | Deans Honor List, American University of Beirut, Lebanon |
| 1988 | BS Biology with Distinction Award, American University of Beirut, Lebanon |
| 2000 | AACR Aspen Workshop on Molecular Biology in Cancer Research |
| 2000-2001 | Amgen Fellow of the Year Award, University of Pittsburgh Medical Center, Pittsburgh, PA |
| 2002 | MD Anderson Travel Award; Breast Cancer Medical Oncology Meeting for Fellows |
| 2006-2007 | Best Teaching Attending of the Year, Roswell Park Cancer Institute |
| 2009-2010 | Best Doctors in America |
| 2009-2010 | Best Teaching Attending of the Year, Roswell Park Cancer Institute |
| 2010 | Best Teaching Attending of the Year, Roswell Park Cancer Institute |
| 2010-2011 | Best Teaching Attending of the Year, Roswell Park Cancer Institute |
| 2011-2017 | America's Top Doctors (Castle Connolly) |
| 2013-2017 | America's Top Doctors for Cancer (Castle Connolly) |
| 2013-16 | Los Angeles Top Doctors (Castle Connolly) |

Memberships and Professional Societies

1999 - American Society of Clinical Oncology (ASCO)
1999 - American Association of Cancer Research (AACR)
2000 - European Society of Medical Oncology (ESMO)
2002-2011 Cancer and Leukemia Group B (CALGB)
2003-2011 American College of Surgeons Oncology Group (ACOSOG)
2009-2011 North America Neuroendocrine Tumor Society (NANETS)
2011- Southwest Oncology Group (SWOG)
2015- NRG

Editorial Positions, Boards and Peer-Review Service

Editorial Boards

Chemotherapy (Member)	2005-2008
Cancer Chemotherapy and Pharmacology (Member)	2009-
Oncology (Member)	2010-
Journal of Gastrointestinal Oncology (Member)	2010-
Colorectal Cancer (Member)	2011-
2016 ASCO Educational Book Expert Panel	2016
2017 ASCO Educational Book Expert Panel	2017

Peer-Review (2005-2017)

American Journal of Clinical Oncology
Annals of Oncology
Asia-Pacific Journal of Clinical Oncology
British Journal of Cancer
British Journal of Surgery
BioMed Central Cancer
Cancer
Cancer Chemotherapy and Pharmacology
Cancer Investigation
Cancer Research
Clinical Cancer Research
Clinical Colorectal Cancer
Chemotherapy
Colorectal Cancer
Critical Reviews in Oncology/ Hematology
Digestive Diseases and Sciences
Diseases of Colon and Rectum
Diseases of the Esophagus
European Journal of Cancer
Expert Opinion on Pharmacotherapy
Expert Review of Anticancer Therapy
International Journal of Cancer
International Journal of Gastrointestinal Cancer
Investigational New Drugs

JAMA Oncology
 Journal of Clinical Oncology
 Journal of Gastrointestinal Oncology
 Journal of Geriatric Oncology
 Journal of Surgical Oncology
 Lung Cancer
 Medical Oncology
 Molecular Cancer
 Oncology
 Surgical Oncology
 The Physician and Sports Medicine
 The Lancet Oncology
 The Oncologist

Teaching

Didactic Course, Curriculum Development

- | | |
|--|-------------|
| 1. Facilitator Host Defenses Course- Medicine I, University of Pittsburgh Medical Center, Pittsburgh, PA | 2001-2002 |
| 2. Curriculum for Fellows: Lower Gastrointestinal Cancers (LGI) Lecture Series; Roswell Park Cancer Institute, Buffalo, NY | 2002 – 2011 |
| 3. Curriculum for Fellows: Colorectal Cancer, U of Michigan | 2012 |
| 4. Curriculum for Fellows: Colorectal Cancer, City of Hope, CA | 2013 - |

Committee, Organizational and Volunteer Service

A. Institutional

2004 -11	Therapeutics Committee Member (RPCI)
2004 -11	Pharmacokinetic and Pharmacodynamic Committee Member
2004 -11	RPCI Peer Review Committee Member
2005 - 2010	Roswell Park Grand Rounds Professional Coordinator
2006 - 10	Roswell Park - ACS local grant review committee
2006 -11	Alliance Grant (RPCI) Review Committee Member
2007 -11	RPCI Off-Label Committee Member
2011-2012	CTRAC Committee Member, University of Michigan
2013-2014	CIS Physician Design Committee, City of Hope
2013-2014	DSMC Associate Chair, City of Hope
2015	Medical Executive Committee, City of Hope
2015	Medical Oncology Chair Search Committee
2015 -	Appointments and Promotions Committee
2015 -	International Medicine Committee
2015-	Internal Funding Prioritization Committee
2015-16	PSA Physician Advisory Committee
2015-	PSA Academic Subcommittee
2016	Medical Specialties Chair Search Committee
2016	Supportive Care Chair Search Committee

2016- Academic Promotion Committee

B. National

2002 - 2012 Member, NCCN Colon/Rectal/Anal Cancer Panel
2010 - ASCO Cancer Foundation Grants Selection Committee Member
2012- SWOG GI Committee Member
2015- NRG GI Core Committee Member
2015- NRG Colorectal Cancer Core Committee Member
2016 NCCN 2016 YIA selection committee
2016 ACCRU Gastrointestinal Cancer Committee
01/2017- NCCN Guidelines Steering Committee representative
06/2017- NCCN Investigator Steering Committee member

Invited Presentations

1. "Recent in the Treatment of Metastatic Colon Cancer" – Grand Rounds Presentation WCA Hospital, Jamestown NY; October 29, 2003.
2. "Recent Advances in the Treatment of Metastatic Colon Cancer" – Department of Internal Medicine, Grand Rounds Presentation. Millard Fillmore Hospital, Buffalo NY; November 10, 2003.
3. "Recent Advances in the Treatment of Metastatic Colon Cancer" – Grand Rounds Presentation. Sisters of Charity Hospital, Buffalo NY. February 24, 2004.
4. "Advances in the Treatment of Colorectal Cancer"- Grand Rounds Presentation, Rochester General Hospital, Rochester NY. May 5, 2004.
5. "Management of Metastatic Colorectal Disease". 2004 NCCN Guidelines Symposium on Colon, Rectal and Anal Cancer Guidelines. Roswell Park Cancer Institute, Buffalo NY. September 13, 2004.
6. "New Therapies in the Treatment of Colorectal Cancer". Mini Medical School, SUNYAB – Buffalo NY. October 12, 2004.
7. "Recent Advances in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer." American College of Surgeons, Western NY Chapter. Buffalo NY. October 21, 2004.
8. "Metastatic Colorectal Cancer: Chemotherapy and Beyond". Roswell Park Cancer Institute, Pharmacy Oncology Symposium, Hyatt Regency, Buffalo NY. October 29, 2004.
9. "Development of Preclinical Rationale for Phase I/II Clinical Trials: A Focus on Selenium". RPCCN Fall Meeting, Roswell Park Cancer Institute, Buffalo, NY. November 9, 2004. "Gastrointestinal Cancer". Highlights from ASCO 2005. Roswell Park Cancer Institute, Buffalo NY. June 18, 2005.

10. Selenium: A Clinical Update. Selenium Workshop. Roswell Park Cancer Institute, Buffalo NY. October 15, 2005.
11. "Metastatic Colorectal Cancer: Are We Making Progress?" Grand Rounds Presentation. Cayuga Medical Center, Ithaca, NY. March 17, 2006.
12. "Developing HDAC inhibitors in the treatment of Metastatic colorectal cancer." Department of Medicine, Research Meeting, Roswell Park Cancer Institute, Buffalo NY. August 1, 2006.
13. "Neoadjuvant therapy in the treatment of rectal cancer." Department of Surgical Oncology, Roswell Park Cancer Institute, "Meet the Professor" series. August 21, 2006
14. "Rethinking Current Strategies in the First –Line Treatment of Metastatic Colorectal Cancer." Roswell Park Cancer Institute, Medical Grand Rounds. September 22, 2006.
15. "The Development of High Dose Selenium Therapy in the Management of Advanced Cancers". Roswell Park Cancer Institute. Prevention Grand Rounds, October 13, 2006
16. "Advances in the Treatment of Metastatic Colorectal Cancer". State of the Art Treatment of Gastrointestinal Cancers Symposium, Detroit, MI. November 11, 2006
17. "Focus on Colorectal Cancer". Roger Williams Medical Center, Providence, RI: Medical Grand Round, January 16, 2007
18. "The Continuum of Colon Care: Issues for the Primary Care Physician and Medical Oncologist". CME - Menorah Medical Center, Kansas. January 30, 2007
19. "Colorectal Cancer: Who is at Risk?" Wisconsin Nurses Association, 9th Annual: Evolving Science of Cancer Treatments and Bone Marrow Treatments, New Orleans. February 28, 2007.
20. "Sequential Tumor Biopsies in Colorectal Cancer Studies at RPCI: Bridging the Gap between the Laboratory and the Clinic". Therapeutics Grand Rounds, Roswell Park Cancer Institute, March 7, 2007.
21. "Combination Chemotherapy in the Neoadjuvant treatment of locally advanced rectal cancer: The more the better?" Karmanos Cancer Institute Grand Rounds, Detroit, MI, March 29, 2007
22. "Colorectal Cancer: Current Progress and Future Directions". ECMC Grand Rounds, Buffalo, NY, May 4th, 2007
23. "Investigating biological markers of response in rectal cancer: lessons learned from a CAPOX/RT neoadjuvant study". Oncology Seminar, Case Western University, Cleveland, OH. September 18, 2007

24. "Integrating Oxaliplatin in the Neoadjuvant Treatment of Rectal Cancer: Is More Better?" Oncology Presentation. University of Chicago, IL, October 22, 2007
25. "Systemic Chemotherapy for Metastatic Colorectal Cancer to the Liver". Third Annual GI Cancer Symposium. University of Cincinnati, OH, November 3, 2007
26. "Improved Phase I Design Issues/Phase I Studies in Healthy Volunteers". Accelerating Anticancer Agent (AAA) Development & Validation Workshop. Bethesda, MD, June 19, 2008.
27. "EGFR Therapy in Colorectal Cancer". Oncology Rounds, Staten Island University Hospital. Staten Island, NY. August 1, 2008.
28. "Post ASCO Review on EGFR Therapy". Oncology Rounds, Whittingham Cancer Center. Norwalk, CT, August 11, 2008.
29. "Anti-EGFR Therapy in Colorectal Cancer". Scott and White Hospital Oncology Grand Rounds, Temple, TX, September 15, 2008
30. "Advances in Metastatic Colorectal Cancer to the Liver". Albany Memorial Hospital Oncology Tumor Board, Albany, NY, September 23, 2008.
31. "Targeted Therapy in Metastatic Colorectal Cancer". Society of Utah Medical Oncologists Annual Meeting. October 2008.
32. "Metastatic Colorectal Cancer: The March towards Cure". Erie County Medical Center Medical Grand Rounds, Buffalo NY, April 8, 2009
33. "Anti-EGFR Therapy in Metastatic Colorectal Cancer". Roger Maris Cancer Center, Fargo, ND, April 17, 2009
34. "Anti-EGFR Therapy in Colorectal Cancer". Tom Baker Cancer Center GI Oncology Rounds, Calgary, ON. April 27, 2009
35. "A Clinical Update on anti-EGFR Therapy in MCRC". London Regional Cancer Center, London, ON. May 5, 2009
36. "Metastatic Colorectal Cancer: A Clinical Update". VA Medical Center, Buffalo NY, Medical Grand Rounds, June 16, 2009
37. "Post-ASCO 2009 Review on GI Cancer". 2009 Highlights from ASCO Symposium, RPCI, Buffalo NY. July 11, 2009
38. "Advances in Metastatic Colorectal Cancer", Holy Name Hospital, New Jersey, September 28, 2010
39. "Systemic Chemotherapy for Metastatic and Localized Colorectal Cancer", Update 2011 – Symposium on the Multidisciplinary Management of Colorectal Cancer – St. John Hospital and Medical Center, March 9, 2011

40. "HDAC Inhibition in Metastatic Colorectal Cancer", Medical Oncology Grand Rounds, University of Cincinnati, Cincinnati, OH, April 7, 2011
41. "Metastatic Colorectal Cancer: From Palliative Care to Curative Therapy", St. John Hospital and Medical Center Quarterly Oncology Grand Rounds, September 8, 2011
42. "Metastatic Colorectal Cancer: From Palliative Therapy To Curative-Intent Treatment", Oncology Quarterly Grand Rounds, St John's Hospital, Grosse Pointe, MI, September 12, 2011
43. "Vitamin D: Any Role in the Adjuvant and Metastatic Colorectal Cancer", Chemotherapy Foundation Symposium, NY, NY, November 9, 2011
44. "Current Strategies in the Neoadjuvant Treatment in Rectal Cancer", University of Michigan, Colorectal Surgery Rounds. January 27, 2012
45. "Neoadjuvant treatment of rectal cancer: is there an optimal strategy", ASCO-SCF-King Fahd Hospital joint conference, Damam, Saudi Arabia, March 5-8, 2012
46. "Management of Metastatic Colorectal Cancer in the Current Biomarkers Era", Medical Oncology Grand Rounds, City of Hope, Duarte, CA, February 5th, 2013
47. "Meet the Experts: Colorectal Cancer", City of Hope Outreach Lecture, City of Hope, Duarte CA, March 27th 2013
48. "Exploring Mechanisms of Resistance to anti-EGFR Therapy in Colorectal Cancer: Opportunities and Challenges", City of Hope All Campus Rounds, Duarte, CA, April 16th 2013
49. ASCO 2013: A Review of Practice Changing Research, City of Hope, July 11th 2013
50. GEST 2014, San Francisco: Integrating radioembolization with chemotherapy in the management of metastatic colorectal cancer: first or second line?" May 1st, 2014
51. GEST 2014, San Francisco: MCRC: current agents, regimen, and toxicities. May 2nd, 2014
52. City of Hope Grand Rounds: "Optimizing Treatment of Metastatic Colorectal Cancer". City of Hope, Duarte, CA. July 8th, 2014
53. "Integrating Y90 into the current paradigm for liver mCRC treatment". World Conference of Interventional Radiology, Buenos Aires, Argentina, October 17th, 2014
54. "Sequencing of treatment in metastatic colorectal cancer". 5th Annual Winship Gastrointestinal Cancer Symposium, Atlanta, Georgia, November 8, 2014.
55. "Developmental Therapeutics: GI Cancer Program". Developmental Cancer Therapeutics Annual Retreat, City of Hope, February 7, 2015

56. "Molecular Profiling in Colorectal Cancer". Community Practices Quarterly Dinner Meeting, City of Hope, April 9, 2015
57. "When Colorectal Cancer Spreads to the Liver". Fight Colorectal Cancer Webinar, May 26, 2015
58. "When to Add Biologicals in Colorectal Cancer". Educational Session, ASCO 2015, May 30, 2015
59. "Is Targeted Radiation with SIR-Spheres® Y-90 resin microspheres an Option for Me?" Colon Cancer Alliance Webinar, July 13, 2015
60. "MEK Inhibitors in Colorectal Cancer." 11th Annual California Cancer Consortium Conference. Pasadena, CA, August 9, 2015
61. "Clinical Breakthroughs in Metastatic Colorectal Cancer: Past and Present". Medical Grand Rounds, Harbor UCLA, September 29, 2015
62. "Integrating Y-90 Radioembolization in the Management of Metastatic Colorectal Cancer", Lebanese Medical Society of Oncology Annual Meeting, April 9, 2016
63. "MCRC: What is the standard of care (chemotherapy, biotherapy, surgery?), GEST Meeting, NY, May 2016
64. "Debate: SIRFLOX results have changed my standard practice", GEST Meeting, NY, MAY 2016

Patent

1. "Method of Augmenting Antitumor Activity of Anticancer Agents" Serial No. 11/405,377 (Rustum Y, Fakih M).

Bibliography

Peer-Reviewed Journals and Publications

1. **Fakih M**, Yagoda A, Pienta KJ. Inhibition of Prostate Cancer Growth by Estramustine and Colchicine. Prostate 1995; 26:310-305.
2. **Fakih M**, Schiff D, Erlich R, Logan T. Intramedullary Spinal Cord Metastasis (ISCM) in Renal Cell Carcinoma; A Series of Six Cases. Ann Oncol 2001; 2:1173-77.
3. **Fakih M**, Defrances MC, Ohri NP, Ramanathan RK. Angiosarcoma of the Scalp Responding to Paclitaxel. J Clin Oncol 2001; 19:4173-79.

4. **Fakih M**, Trump DL, Johnson C. Glucocorticoids and treatment in prostate cancer: a preclinical and clinical review. *Urology* 2002; 670:553.
5. Zamboni WC, Jung LL, Egorin MJ, Potter DM, Friedland DM, Belani CP, Agarwala SS, Wong MM, **Fakih M**, Trump DL, Jin R, Strychor S, Vozniak M, Troetschel M, Ramanathan RK. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors. *Clin Cancer Res.* 2004 Aug 1; 10: 5058-64.
6. Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, **Fakih M**, Yu WD, Johnson CS. Anti-tumor activity of calcitriol: pre clinical and clinical studies. *J Steroid Biochem & Mol Biol* 2004; 89:519-526.
7. Reid ME, Stratton MS, Lilloco AJ, **Fakih M**, Natarajan R, Clark LC, Marshall JR. A report of high-dose selenium supplementation: response and toxicities. *J Trace Elem Med Biol* 2004; 18:69-74.
8. **Fakih M**. 5 Fluorouracil Leucovorin and Oxaliplatin (FOLFOX) in the Treatment of Metastatic Colon Cancer with Severe Liver Dysfunction. *Oncology* 2004; 67: 222-224.
9. Jung LL, Ramanathan RK, Egorin MJ, Jin R, Belani CP, Potter DM, Strychor S, Trump DL, Walko C, **Fakih M**, Zamboni WC. Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. *Cancer Chemother Pharmacol* 2004; 54: 487-496.
10. Mortazavi A, Shaukat A, Othman E, Kepner JL, **Fakih MG**, Kuvshinoff BW, Smith JL, Javle MM. Postoperative computed tomography scan surveillance for patients with stage II and III colorectal cancer: worthy of further study? *Am J Clin Oncol* 2005; 28: 30-35.
11. Ramanathan RK, Ramalingam S, Egorin MJ, Belani CP, Potter DM, **Fakih M**, Jung LL, Strychor S, Jacobs SA, Friedland DM, Shin DM, Chatta GS, Tutchko T, Zamboni WC. Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. *Cancer Chemother Pharmacol* 2005; 55: 354-360.
12. **Fakih M**, Ip C, Reid M, Sunga A, Rustum Y. Selenium supplementation: Protection against chemotherapy induced toxicity and enhancement of antitumor activity? *Supp Pall Cancer Care* 2005, 2: 3-9.
13. **Fakih M**, Cao S, Durrani FA, Rustum YM. Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors. *Clin Colorectal Cancer.* 2005 Jul; 5 (2):132-5.
14. **Fakih MG**, Creaven PJ, Ramnath N, Trump D, Javle M, Strychor S, Repinski TVW, Zamboni BA, Schwarz JK, Frence RA, Zamboni WC. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine (DPC) in patients with advanced solid tumors. *Clin Cancer Res* 2005 Aug 15; 11; (16): 5942-5949.

15. Engstrom PF, Benson AB 3rd, Chen YJ, Choti MA, Dilawara RA, Enke CA, **Fakih MG**, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW Jr, Rao S, Saif MW, Saltz L, Skibber JM, Vernook AP, Yeatman TJ. Anal Canal Cancer. J Natl Compr Canc Netw. 2005; (4): 510-515.
16. Engstrom PF, Benson AB 3rd, Chen YJ, Choti MA, Dilawara RA, Enke CA, **Fakih MG**, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW Jr, Rao S, Saif MW, Saltz L, Skibber JM, Vernook AP, Yeatman TJ. Rectal Cancer. J Natl Compr Canc Netw. 2005; (4): 492-508.
17. Engstrom PF, Benson AB 3rd, Chen YJ, Choti MA, Dilawara RA, Enke CA, **Fakih MG**, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW Jr, Rao S, Saif MW, Saltz L, Skibber JM, Vernook AP, Yeatman TJ. Colon Cancer. J Natl Compr Canc Netw. 2005; (4): 492-508.
18. **Fakih M**, Shousong C, Durrani F, Rustum YM. Selenium protects against toxicity induced by anticancer drugs and augments anticancer activity: A highly selective, new, and novel approach for the treatment of solid tumors. Clin Colorectal Cancer. 2005; 5:132-5.
19. Reid ME, Duffield-Lillico AJ, Sunga A, **Fakih M**, Alberts DS, Marshall J. Selenium Supplementation and Colorectal Adenomas: An Analysis of the Nutritional Prevention of Cancer Trial. Int J Cancer. 2006 Apr 1;118 (7):1777-81.
20. Ramanathan RK, **Fakih M**, Main S, Deutsch M, Perez RP, Ritter MA, Eiseman JL, Ivy SP, Trump DL, Belani CP, Parise RA, Potter DM, Egorin MJ. Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. Cancer Chemother Pharmacol. 2006 Apr;57(4):465-74.
21. Cao S, Bhattacharya A, Durrani F, **Fakih M**. Irinotecan, Oxaliplatin and Raltitrexed for the Treatment of Advanced Colorectal Cancer Expert Opinion on Pharmacology 2006 Apr;7(6):687-703.
22. Padmanabhan A, **Fakih, M**. CEA Monitoring in Colorectal Cancer: What You Should Know. Oncology 2006 May; 20(6):579-87.
23. Ailawadhi S, Sunga A, Rajput A, Yang GY, Smith J, **Fakih M**. Chemotherapy-Induced Carcinoembryonic Antigen (CEA) Surge in Patients with Metastatic Colorectal Cancer. Oncology 2006; 70 (1):49-53.
24. **Fakih MG**, Pendyala L, Smith PF, Creaven PJ, Reid ME, Badmaev V, Azrak RG, Prey JD, Lawrence D, Rustum YM. A Phase I and Pharmacokinetic Study of Fixed Dose Selenomethionine and Irinotecan in Solid Tumors. Clin Cancer Res 2006 Feb 15; 12(4):1237-1244.
25. Trump DL, Muindi J, **Fakih M**, Yu WD, Johnson C. Vitamin D Compounds: Clinical Development as Cancer Therapy and Prevention Agents. Anticancer Res 2006 Jul-Aug; 26 (4A):2551-56.

26. **Fakih M.** Gemcitabine-Induced Rectus Abdominus Radiation Recall. *Journal of the Pancreas* 2006 May 9;7(3):306-10.
27. **Fakih MG, A, Yang GY, Pendyala L, Toth K, Smith JL, Lawrence DD, Rustum YM.** A Phase I Study of Weekly Intravenous Oxaliplatin in Combination with Oral Daily Capecitabine and Radiation Therapy in the Neoadjuvant Treatment of Rectal Adenocarcinoma. *International J Rad Oncol, Biol, Phys* 2006 Aug 1;65(5):1462-70.
28. Cao S, Bhattacharya A, Durrani F, **Fakih M.** Irinotecan, Oxaliplatin and Raltitrexed for the Treatment of Advanced Colorectal Cancer. *Expert Opin Pharmacother.* 2006 Apr; 7 (6): 687-703.
29. **Fakih MG,** Wilding G, Lombardo J. Cetuximab-Induced Hypomagnesemia in Patients with Colorectal Cancer. *Clin Colorectal Cancer.* 2006 Jul;6(2):152-6.
30. Bir A, Bshara W, George M, **Fakih MG.** Idiopathic thrombocytopenic purpura in a newly diagnosed pancreatic adenocarcinoma. *JOP.* 2006 Nov 10;7(6):647-50.
31. Qureshi KM, Raman AK, Tan D, **Fakih MG.** Leukemoid reaction in pancreatic cancer: a case report and review of the literature. *JOP.* 2006 Nov 10;7(6):631-4.
32. **Fakih MG,** A Sunga. Prevention of Colorectal Cancer: An Emerging Role for High Dose Vitamin D Supplementation? *Oncology* 2006; 20: 1707-1710.
33. Reddy N, Yu J, **Fakih, MG.** Toxicities and Survival among Octogenarians and Nonagenarians with Colorectal Cancer (CRC) Treated with Chemotherapy or Concurrent Chemoradiation. *Clin Colorectal Cancer* 2007 Jan;6(5):362-6.
34. Kuehnelt D, Juresa D, Francesconi KA, **Fakih M,** Reid ME. Selenium metabolites in urine of cancer patients receiving L-selenomethionine at high doses. *Toxicology and Applied Pharmacology* 2007 Apr 15;220(2):211-5.
35. **Fakih, M;** Trump, D; Muindi, J; Black, J; Bernardi, R; Creaven, P; Schwartz, J; Brattain, M; Hutson, A; French, R; Johnson, C. A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid Tumors. *Clinical Cancer Research.* 2007 Feb 15;13(4):1216-23.
36. Azrak RG, Cao S, Pendyala L, Durrani FA, **Fakih M,** Combs GF Jr, Prey J, Smith PF, Rustum YM. Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent. *Biochem Pharmacol.* 2007 May 1;73(9):1280-7.
37. **Fakih M.** Anti-EGFR monoclonal antibody-induced hypomagnesaemia. *Lancet Oncology.* 2007 May; 8(5):366-7.
38. Raman AK, **Fakih MG.** Capecitabine-Induced Headache Responding to Diltiazem. *Chemotherapy.* 2007 May 25;53(4):306-308.

39. Gupta B, LeVeae C, Litwin A, **Fakih MG**. Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab. Clin Colorectal Cancer. 2007 Mar;6(6):447-9.
40. Bir A, Tan W, Wilding G, Lombardo J, **Fakih MG**. '5-FU, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab in the first line treatment of metastatic colorectal cancer: a single institute study. Oncology. 2007 Oct 30;72(1-2):4-9.
41. Iyer R, Gibbs J, Kuvshinoff B, **Fakih MG**, Lawrence D, Javle M. A Phase II Study of Gemcitabine and Capecitabine in Advanced Cholangiocarcinoma and Carcinoma of the Gall Bladder- A Single Institution Prospective Study. Ann Surg Oncol. 2007 Nov; 14(11):3202-9.
42. **Fakih MG**, Ross ME, Starostik P. Increased Frequency of UGT1A1 7/7 in Patients Experiencing Severe Irinotecan-Induced Toxicities. Clinical Colorectal Cancer. 2007 July; 6 (8):583-87.
43. Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, **Fakih MG**, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW Jr, Rao S, Saltz L, Shibata D, Skibber JM, Venook AP. Colon Cancer. J Natl Compr Canc Netw. 2007 Oct; 5(9):884-925.
44. Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, **Fakih MG**, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW Jr, Rao S, Saltz L, Shibata D, Skibber JM, Venook AP. J Natl Compr Canc Netw. Rectal Cancer. 2007 Oct; 5(9):940-81.
45. Puthillath A, BullardDunn K, Rajut A , Smith J, Yang G, Wilding G, Tan W, Gupta B, **Fakih MG**. Safety and Efficacy of Upfront Chemotherapy in Unresected Metastatic Colorectal Cancer. Clinical Colorectal Cancer 2007 Nov; 6(10):710-5.
46. Pande R, Sunga A, LeVeae C, Wilding GE, Bshara W, Reid M, **Fakih, MG**. Significance of Signet Ring Cells in Colorectal Cancer Patients. Diseases of the Colon and Rectum. 2008, 51: 50-5.
47. Hector S, Tummala R, Kiseil ND, Diegelman P, Vucic S, Clark K, **Fakih M**, Kramer DL, Porter C, Pendyala L. Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and *N1, N11* diethylnorspermine. Cancer Chemotherapy and Pharmacology 2008, 62: 517-27.
48. **Fakih M**, Pendyala L, Brady W, Smith P, Ross M, Creaven P, Badmaev V, Prey J, Rustum Y. A Phase I and Pharmacokinetic Study of Selenomethionine in Combination with a Fixed Dose Irinotecan in Solid Tumors. Cancer Chemotherapy and Pharmacology 2008, 62: 499-508.
49. **Fakih MG**, Management of Anti-Epidermal Growth Factor Receptor Targeting Monoclonal Antibody-Induced Hypomagnesemia. Oncology (Williston Park). 2008 Jan; 22(1):74-6.

50. **Fakih MG**, BullardDunn, K, Yang GY, Pendyala L, Toth K, Andrews C, Rustum YM, Ross ME, LeVeae C, Puthillath A, Park YM, Rajput A. A Phase II Study of Weekly Intravenous Oxaliplatin in Combination with Oral Daily Capecitabine and Radiation Therapy with Biological Correlates in the Neoadjuvant Treatment of Rectal Adenocarcinoma. *Int J Rad Oncol Biol Phys*. 2008. 72: 650-7.
51. Gottlieb RH, Litwin A, Gupta B, Taylor J, Raczyc C, Mashtare T, Wilding G, **Fakih M**. Qualitative radiology assessment of tumor response: does it measure up? *Clin Imaging*. 2008 Mar-Apr; 32(2):136-40.
52. Patel A, Puthillath A, Yang G, **Fakih MG**. Neoadjuvant chemoradiation for rectal cancer: Is more better? *Oncology (Williston Park)*. 2008 Jun;22(7):814-26.
53. **Fakih, MG**. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach? *Expert Review of Anticancer Therapy*. 2008 Sep;8(9):1471-80.
54. **Fakih, MG**. The role of targeted therapies in the treatment of advanced colorectal cancer. *Current Treatment Options in Oncology*. 2008 Dec; 9 (4-6): 357-74.
55. **Fakih, MG**. Does celecoxib have a role in the treatment of colorectal cancer? *Clinical Colorectal Cancer*. 2009 Jan; 8 (1): 11-4.
56. Puthillath A, Patel A, **Fakih MG**. Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. *Onco Targets and Therapy* 2009;2 1–15.
57. **Fakih MG**, Trump DL, Johnson CS, Tian L, Muindi J, Sunga AY. Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. *Int J Colorectal Dis*. 2009 Feb;24 (2):219-24.
58. Fora A, Alabsi E, **Fakih MG**. A Case of 5- Fluorouracil Induced Acute Psychosis. *Clinical Colorectal Cancer*. 2009 Jul; 8 (3): 166-8.
59. Puthillath A, Mashtare T , Wilding G, Khushalani N, Steinbrenner L, Ross ME, Romano K, Wisniewski M, **Fakih MG**. A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. *Critical Reviews in Hematology/Oncology* 2009 Sep; 71 (3): 242-8.
60. Trump DL, Chadha MK, Sunga AY, **Fakih MG**, Ashraf U, Silliman CS, Hollis BW, Nesline M, Tian L, Tan W, Johnson CS. Vitamin D Deficiency and Insufficiency among Prostate Cancer Patients. *Brit J Urology*. 2009 Oct;104(7):909-14.
61. Antonius A. Miller, Daryl J. Murry, Kouros Owzar, Donna R. Hollis, Erin B. Kennedy, Ghassan Abou-Alfa, Apurva Desai, Jimmy Hwang, Miguel A. Villalona-Calero, E. Claire Dees, Lionel D. Lewis, **Marwan G. Fakih**, Martin J. Edelman, Fred Millard, Richard C. Frank, Raymond J. Hohl, and Mark J. Ratain. Phase I and Pharmacokinetic Study of Sorafenib in Patients with Hepatic or Renal Dysfunction: Cancer and Leukemia Group B Study 60301. *J Clin Oncol* 2009; 27:1800-5.

62. Angitapalli R, Litwin AM, Kumar PRG, Nasser E, Lombardo J, Mashtare T, Wilding GE, **Fakih MG**. Adjuvant FOLFOX Chemotherapy and Splenomegaly in Patients with Stages II-III Colorectal Cancer. *Oncology* 2009;76 (5):363-8.
63. **Fakih MG**, Pendyala L, Fetterly G, Toth K, Zwiebel JA, Espinoza-Delgado I, Litwin A, Rustum YR, Ross ME, Holleran JL, and Egorin MJ. A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer. *Clin Cancer Res* 2009, 15: 3189-95.
64. Muindi JR, Johnson CS, Trump DL, Christy R, Engler KL, and **Fakih MG**. A Phase I and Pharmacokinetics Study of Intravenous Calcitriol in Combination with Oral Dexamethasone and Gefitinib in Patients with Advanced Solid Tumors. *Cancer Chemotherapy and Pharmacology* 2009, 65 (1): 33-40.
65. Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, **Fakih MG**, Fleshman J Jr, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. *J Natl Compr Canc Netw*. 2009 Sep;7(8):838-881.
66. Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, **Fakih MG**, Fleshman J Jr, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. *J Natl Compr Canc Netw*. 2009 Sep;7(8):778-831.
67. May KS, Khushalani NI, Chandrasekhar R, Wilding GE, Iyer RV, Ma WW, Flaherty L, Russo RC, **Fakih M**, Kuvshinoff BV, Gibbs J, Javle MM, Yang GY. Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies following chemoradiation to the abdomen. *Int J Rad Oncol Biol* 2010; 76(4): 1193-1198.
68. Yang GY, May KS, Iyer RV, Chandrasekhar R, Wilding GE, McCloskey SA, Khushalani NI, Yendamuri SS, Gibbs JF, **Fakih MG**, Thomas CR. Renal Atrophy Secondary to Chemoradiotherapy of Abdominal Malignancies. *Int J of Biol Oncol and Physics* 2010; 78(2): 539-546.
69. **Fakih, MG**. KRAS Mutation Screening in Colorectal Cancer: From Paper to Practice. *Clin Colorectal Cancer* 2010, 9(1): 22-30.
70. Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, **Fakih MG**, Fleshman J Jr, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma. *J Natl Compr Canc Netw*. 2010 Jan;8(1):106-20.

71. Vaidyanathan G, **Fakih MG**. A Case of curative-intent hepatectomy for metastatic colon cancer to the scapula and liver. *Anticancer Research*. 2010; 30: 677-9.
72. Abbas A, Yang G, **Fakih MG**. Management of Anal Cancers in 2010: Overview Screening and Diagnosis. *Oncology*, 2010; 24: 364-369.
73. Abbas A, Yang G, **Fakih MG**. Management of Anal Cancers in 2010: Current Treatment Standards and Future Directions. *Oncology*, 2010; 24: 417-424.
74. **Fakih MG**, Fetterly G, Egorin MJ, Muindi JR, Espinoza-Delgado I, Zwiebel JA, Litwin A, Holleran JL, Wang K, Diasio RB. A Phase I Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors. *Clin Cancer Res*. 2010 May 12; 16(14): 3786-3794.
75. Reidy DL, Vakiani E, **Fakih MG**, Saif MW, Hecht JR, Goodman-Davis N, Hollywood E, Shia J, Schwartz J, Chandrawansa K, Dontabhaktuni A, Youssofian H, Solit DB, Saltz LB. A Randomized Phase II Study of the Insulin-Like Growth Factor-1 Receptor (IGF-1R) Inhibitor IMC-A12, with or without Cetuximab, in Patients with Cetuximab or Panitumumab-Refractory Metastatic Colorectal Cancer. *J Clin Oncol* 2010; 28(27): 4240-4246.
76. Vaidyanathan G, Groman A, Wilding G, **Fakih MG**. Stop and Go FOLFOX Bevacizumab Chemotherapy in the First Line Treatment of Metastatic Colorectal Cancer. *Oncology* 2010;79(1-2):67-71.
77. **Fakih M**, Wong R. Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer. *Current Oncology* 2010, Volume 17: S3-S17.
78. **Fakih M**, Vincent M. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. *Current Oncology* 2010, Vol 17: S18-S30.
79. Hopkins S, **Fakih M**, Yang G. Positron emission tomography as predictor of rectal cancer response during or following neoadjuvant chemoradiation *World J Gastrointest Oncol* 2010; 2: 213-217.
80. Wagner T, **Fakih M**, Yang G. Management Stage II/III Rectal Cancer. *J Gastrointest Oncol*. 2010 Dec; 1(2): 112-9.
81. Puthillath A, Trump DL, Andrews C, Bir A, Romano K, Wisniewski M, **Fakih MG**. Serological immune responses to influenza vaccine in patients with colorectal cancer. *Cancer Chemother Pharmacol*. 2011; 67: 111-5
82. Chadha MK, **Fakih M**, Muindi J, Tian L, Mashtare T, Johnson CS, Trump D. Effect of 25-hydroxyvitamin D status n serological response to influenza vaccine in prostate cancer patients. *Prostate* 2011; 71(4): 368-372.
83. Advani PP, **Fakih MG**. 5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine. *Anticancer Research* 2011; 31(1): 335-8.

84. **Fakih MG.** Making sense of anti-EGFR plus oxaliplatin-based therapy in the first-line treatment of metastatic colorectal cancer. *Future Oncol* 2011; 7(2); 223-6.
85. Patta A, **Fakih MG.** First-line Cisplatin Plus Etoposide in High Grade Metastatic Neuroendocrine Tumors of Colon and Rectum (MCRC NET): Review of 8 Cases. *Anticancer Research* 2011; 31: 975-8
86. Marshall JR, Ip C, Romano K, Fetterly G, **Fakih MG,** Jovanovic BD, Perloff M, Crowell J, Davis W Jr, Christy R, Dew A, Coomes M, Bergan RC. Methyl Selenocysteine: single-dose pharmacokinetics in men. *Cancer Prev Res*, 2011 Nov;4(11):1938-44
87. Abbas A, Neimeh E, **Fakih MG.** Single Agent Paclitaxel in Advanced Anal Cancer after Failure of Cisplatin and 5-Fluorouracil Chemotherapy. *Anticancer Research*, 2011 Dec;31(12):4637-40
88. Fora A, Patta A, Attwood K, Wilding G, and **Fakih MG.** Intensive Radiographic and Biomarker Surveillance in Stages II and III Colorectal Cancer. *Oncology*, 2012 Jan 26;82(1):41-4720
89. Carneiro BA, Ramanathan RK, **Fakih MG,** Krishnamurthi SS, Lembersky BC, Stoller RG, Lancaster SL, Pinkerton RA, Crandall TL, Schmotzer AR, Potter DM, Bahary N. Phase II Study of Irinotecan and Cetuximab Given Every 2 Weeks as Second-Line Therapy for Advanced Colorectal Cancer. *Clin Colorectal Cancer*, 2012 Mar;11(1): 53-9
90. **Fakih MG,** Groman A; McMahon J; Wilding G; Muindi J. A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. *Cancer Chemotherapy Pharmacol*, 2012 Mar; 69(3):743-51
91. **Fakih, MG.** Intensive Screening for Resected Stage II and III Colorectal Cancer. *Colorectal Cancer*, 2012, Vol. 1, No. 1, Pages 71-81
92. Benson AB 3rd, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, **Fakih MG,** Fleshman JW Jr, Fuchs CS, Grem JL, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett C, Freedman-Cass DA. Anal Carcinoma, Version 2.2012: Featured Updates to the NCCN Guidelines. *J Natl Compr Canc Netw*. 2012 Apr 1;10(4):449-454.
93. **Fakih, MG,** Andrews C, McMahon J, Muindi J. A Prospective Study of Cholecalciferol 2000 IU/day in Colorectal Cancer Patients: Evidence of a Chemotherapy-Response Interaction. *Anticancer Research*, 2012 Apr; 32(4):1333-8
94. Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, **Fakih MG,** Fuchs CS, Grem JL, Hunt S, Leong LA, Lin E, Martin MG, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Freedman-Cass DA, Gregory KM. Rectal Cancer, 2012J *Natl Compr Canc Netw*. 2012 Dec 1;10(12):1528-64.

95. Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. *J Natl Compr Canc Netw*. 2013 Feb 1;11(2):141-52
96. Fora AA, McMahon JA, Wilding G, Groman A, Ma WW, Romano KS, **Fakih MG**. A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan. *Oncology*. 2013;84(4):210-3
97. **Fakih MG**. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer. 2013 Apr;13(4):427-38
98. **Fakih MG**. Targeting Mechanisms of Resistance to anti-EGFR Therapy in KRAS Wild-Type Colorectal Cancer: The Path to a more Personalized Medicine. *Future Oncol*. 2013 Apr;9(4):551-60
99. Haslinger M, Francescutti V, Attwood K, McCart JA, **Fakih M**, Kane JM 3rd, Skitzki JJ. A contemporary analysis of morbidity and outcomes of cytoreduction/hyperthermic intraperitoneal chemoperfusion. *Cancer Med*. 2013 Jun;2(3):334-42
100. Luu C, Heinrich EL, Duldulao M, Arrington AK, **Fakih M**, Garcia-Aguilar J, Kim J. TP53 and Let-7a micro-RNA Regulate K-Ras Activity in HCT116 Colorectal Cancer Cells. *PLoS One*. 2013 Aug 1;8(8):e70604
101. Arrington AK, Nelson RA, Falor A, Luu C, Wiatrek RL, **Fakih M**, Singh G, Kim J. Impact of medical and surgical intervention on survival in patients with cholangiocarcinoma. *World J Gastrointest Surg*. 2013 Jun 27;5(6):178-86
102. **Fakih, M**. Targeted therapies in colorectal cancer: the dos, don'ts, and future directions. *J Gastrointest Oncol*. 2013 Sep;4(3):239-44.
103. Fuchs CS, **Fakih M**, Schwartzberg L, Cohn AL, Yee L, Dreisbach L, Kozloff MF, Hei YJ, Galimi F, Pan Y, Haddad V, Hsu CP, Sabin A, Saltz L. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. *Cancer*, 2013 Dec 15;119(24):4290-8.
104. Deeb KK, Sram JP, Gao H, **Fakih MG**. Multigene assays in metastatic colorectal cancer. *J Natl Compr Canc Netw*. 2013 Sep 1;11 Suppl 4:S9-S17.
105. **Fakih, MG**. SIR-Spheres[®] radioembolization in the management of metastatic colorectal cancer: a medical oncology perspective. *Colorectal Cancer*, 2014: Vol. 3, No. 4, Pages 331-343
106. Hardwick NR, Carroll M, Kaltcheva TI, Qian D, Lim D, Leong L, Chu P, Kim J, Joseph C, **Fakih MG**, Yen Y, Espenschied J, Ellenhorn JD, Diamond DJ, Chung V. p53MVA

therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T cell responses. *Clin Cancer Res.* 2014 Sep 1;20(17): 4456-70

107. **Fakih, MG.** A case of fibrolamellar cancer with a palliative response and minor radiographic regression with erlotinib and bevacizumab combination therapy. *Am J Ther.* 2014 Nov-Dec;21(6):e207-10
108. Hall MD, Schultheiss TE, Smith DD, **Fakih, MG**, Kim J, Wong JY, Chen YJ. Impact of total lymph node count on staging and survival after neoadjuvant chemoradiation therapy for rectal cancer, *Ann Surg Oncol*, 2015 May 9, (Epub ahead of print)
109. **Fakih MG.** Metastatic colorectal cancer: Current state and future directions. *J Clin Oncol.* 2015 June 1;33(16):1809-1824. Epub 2015 Apr 27. Review.
110. Graham CN, Hechmati G, **Fakih MG**, Knox HN, Maglinte GA, Hjelmgren J, Barber B, Schwartzberg LS. Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. *J Med Econ.* 2015 May 20: 1-10 (Epub ahead of print)
111. Boland PM, **Fakih M.**The emerging role of neoadjuvant chemotherapy for rectal cancer. *J Gastrointest Oncol.* 2014 Oct;5(5):362-73
112. Lee S, Heinrich EL, Lu J, Lee W, Choi AH, Luu C, Chung V, **Fakih M**, Kim J. Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells. *Pancreas.* 2016 Feb;45(2):286-92
113. Cho M, Gong J, **Fakih M.** The state of regional therapy in the management of metastatic colorectal cancer to the liver. *Expert Rev Anticancer Ther*, Jan 2016; 13: 13-17
114. Cho M, Akiba C, Lau C, Smith D, Telatar M, Afkhami M, Sentovich S, Melstrom K, **Fakih M.** Impact of RAS and BRAF mutations on carcinoembryonic antigen production and pattern of colorectal metastases. *World J Gastrointest Oncol.* 2016 Jan 15; 8(1):128-35
115. Sun V, Ruel N, Chung V, Singh G, Leong L, **Fakih M**, Fong Y, Ferrell B. Pilot study of an interdisciplinary supportive care planning intervention in pancreatic cancer. *Support Care Cancer.* 2016 Mar 17.
116. Graham CN, Maglinte GA, Schwartzberg LS, Price TJ, Knox HN, Hechmati G, Hjelmgren J, Barber B, **Fakih MG.** Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. *Clin Ther.* 2016 Jun; 38(6):1376-91
117. Chung V, Frankel P, Lim D, Yeon C, Leong L, Chao J, Ruel N, Luevanos E, Koehler S, Chung S, Lau SC, **Fakih MG.** Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma. *Oncology.* 2016; 90(6):307-12

118. Du L, Li YJ, **Fakih M**, Wiatrek RL, Duldulao M, Chen Z, Chu P, Garcia-Aguilar J, Chen Y. Role of SUMO activating enzyme in cancer stem cell maintenance and self-renewal. *Nat Commun*. 2016 Jul 28; 7:12326
119. Ma WW, Saif MW, El-Rayes BF, **Fakih MG**, Cartwright TH, Posey JA, King TR, von Borstel RW, Bamat MK. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. *Cancer*. 2016 Sep 13. doi: 10.1002/cncr.30321 [Epub ahead of print]
120. Hurria A, Akiba C, Kim J, Mitani D, Loscalzo M, Katheria V, Koczywas M, Pal S, Chung V, Forman S, Nathwani N, **Fakih M**, Karanes C, Lim D, Popplewell L, Cohen H, Canin B, Cella D, Ferrell B, Goldstein L. Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer. *J Oncol Pract*. 2016 Sep 13. pii: JOPR013136. [Epub ahead of print]
121. Rankin A, Klempner SJ, Erlich R, Sun JX, Grothey A, **Fakih M**, George TJ Jr, Lee J, Ross JS, Stephens PJ, Miller VA, Ali SM, Schrock AB. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. *Oncologist*. 2016 Sep 28. pii: theoncologist.2016-0148. [Epub ahead of print]
122. Gong J, Cho M, **Fakih M**. RAS and BRAF in metastatic colorectal cancer management. *J Gastrointest Oncol*. 2016 Oct;7(5):687-704.
123. Hall MD, Schultheiss TE, Smith DD, **Fakih MG**, Wong JY, Chen YJ. Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy. *Acta Oncol*. 2016 Oct 20:1-8. [Epub ahead of print]
124. Lavingia V, **Fakih M**. Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review. *J Gastrointest Oncol*. 2016 Dec;7(6): E98-E102
125. Gong J, Cho M, Sy M, Salgia R, **Fakih M**. Molecular profiling of metastatic colorectal tumors using next-generation sequencing: A single-institution experience. *Oncotarget*. 2017 Feb 2. doi: 10.18632/oncotarget.15030
126. Gong J, Wang C, Lee PP, Chu P, **Fakih M**. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation. *J Natl Compr Canc Netw*. 2017 Feb;15(2):142-147.
127. Gong J, Chen Y, Yang L, Pillai R, Shirasawa S, **Fakih M**. MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. *Anticancer Res*. 2017 Jun;37(6):2831-2838
128. Gong J, Cho M, **Fakih M**. Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. *J Gastrointest Oncol*. 2017 Apr;8(2):314-323
129. Reb A, Ruel N, **Fakih M**, Lai L, Salgia R, Ferrell B, Sampath S, Kim JY, Raz DJ, Sun V. Empowering survivors after colorectal and lung cancer treatment: Pilot study of a

Self-Management Survivorship Care Planning intervention. Eur J Oncol Nurs. 2017 Aug;29:125-134

Book Chapters

1. **Fakih M**, Sunga A, Trump DT. Reproductive Complications, Chapter 64. Abeloff, Clinical Oncology; 3rd edition. 2004; 1269-1285.
2. **Fakih MG**, Sunga A, Muindi J. Vitamin D and Colorectal Cancer, Chapter 13. Trump and Johnson, Vitamin D and Cancer. Springer 2011
3. **Fakih M**. Biologic therapies in colorectal cancer: indications and contraindications. Am Soc Clin Oncol Educ Book. 2015;35:e197-206. doi:10.14694/EdBook_AM.2015.35.e197
4. **Fakih M**. Molecular Biology- Colorectal Cancer, Chapter 4. Stein, Molecular Medicine; 1st edition. 2015; 99-105
5. Sentovich S, **Fakih M**. Colorectal Cancer: Post-Operative Adjuvant Therapy. The ASCRS Textbook of Colon and Rectal Surgery 3rd Edition pp 547-554, online March 2016

Editorials, Letters, and Published Interviews

1. **Fakih M**. First line hepatic infusion of pirarubicin in patients with isolated liver metastases: Is it really promising?" Ann Oncol 2004;15:359.
2. **Fakih M**, Trump DL. Handbook of Anticancer Drug Development. Oncology– July 2005. (Book Review)
3. Lombardo J, **Fakih, M**. Bevacizumab-Induced Nasal Septum Perforation. Oncologist 2006; 11; 85-86.
4. **Fakih MG**. Concurrent Oxaliplatin, Capecitabine, and Radiation Therapy in the Neoadjuvant Therapy of Rectal Adenocarcinoma: Can We Get the Right Dose First?" Annals of Oncology 2006; 17: 1029-30
5. **Fakih MG**. Carcinoembryonic Antigen Monitoring in Metastatic Colorectal Cancer: Words of Caution. J Clin Oncol. 2008 Nov 3. [Epub]
6. **Fakih MG**. Rectal Cancer: Key Issues Reconsidered. Oncology, 2008, 22: 1444-1446
7. **Fakih M**. Integrating Targeted Agents in Metastatic Colorectal Cancer. Colorectal Cancer. 2009; 2: 81-93.

8. **Fakih MG.** Recent Advances in first-line treatment in colorectal cancer: where are we now. *Colorectal Cancer* 1: 111-114, 2012
9. **Fakih MG.** Targeting angiogenesis beyond first-line bevacizumab progression: ziv-aflibercept or more bevacizumab? *Colorectal Cancer*, 2013: Vol. 2, No. 1, Pages 9-12.
10. **Fakih MG.** Vitamin D and colorectal cancer: is it time for D3 supplementation in patients with metastatic disease? *Colorectal Cancer*, 2015: Vol. 4, No. 2, Pages 59-62
11. **Fakih MG.** An update on anti-EGF receptor therapy and the move towards targeted therapy and precision medicine. *Colorectal Cancer*, 2015. Vol. 4, No. 1, Pages 9-11.

Selected Abstracts

1. **Fakih M,** Redner R. Acute Promyelocytic Leukemia t (5; 17) Diffusion Protein NPM-RAR Down Regulates AP-1 Activity in the Presence of ATRA. #1804, AACR 2001.
2. **Fakih M,** Ramanathan RK, Mani S, Parise RA, Long GS, Belani CP, Capozzoli MJ, Trump DL, Egorin MJ. Phase I and Pharmacokinetic Trial of Thrice Weekly Motexafin Gandolinium (MGd) with Daily Radiation Therapy (RT) in Advanced Biliary Tree and Pancreatic Cancers. #454, PRO ASCO, 2001.
3. Trump DL, Egorin MJ, Ramesh RK, Capozzoli MJ, Polakowski S, Wong M, **Fakih M,** Stoller R, Jacobs S, Brufsky A, Mason-Liddil N, Kopit J, Bello A, Gupta E, Ogan M, Zeng J, LaCreta F, Hansel S, Perrone R, Rose W, Tubertini R, Palme T, Griffin T, Malik R. A new oral taxane (BMS-275183) Phase I Trial with Evaluation of Pharmacokinetics, Pharmacodynamics and Bioavailability. #398, PRO ASCO, 2002
4. Zamboni WC, Jung LL, Egorin MJ, Jin R, Wong MK, **Fakih M,** Belani CP, Potter DM, Tauch JS, Walko CW, Strychor S, Sun SL, Trump DL, Ramanathan RK. Phase I Studies of Intermittently Administered 9-Nitrocampothecin (9NC): Relationship Between Daily Doses and Toxicity. #390, PRO ASCO, 2002
5. Chatta GS, **Fakih M,** Belani CP, Ramalingam S, Ramanathan RK, Zamboni W, Parise R, Friedland D, Tutchko S, Egorin MJ. Univ of Pittsburgh Cancer Institute, Pittsburgh, PA. Phase I pharmacokinetic (PK) study of daily imatinib (STI 571) in combination with every 3 week docetaxel for patients with advanced solid tumors. #577, PRO ASCO, 2003
6. Zamboni W, Belani CP, Jung LL, Egorin MJ, Parise RA, Jacobs SA, Potter D, **Fakih M,** Tutchko S, Ramanathan RK. University of Pittsburgh Cancer Institute, Pittsburgh, PA. Phase I and pharmacokinetic (PK) study of weekly docetaxel (D) in combination with capecitabine (C) in patients (pts) with advanced solid tumors. # 555, PRO ASCO, 2003
7. K. Donthireddy, N. Wilkinson, D. Lawrence, **M. Fakih,** A. Rajput, D. Walsh, G. Yang, M. Javle. Roswell Park Cancer Institute, Buffalo, NY. Neoadjuvant chemoradiotherapy for rectal cancer: Clinical experience and prognosis. # 1467, PRO ASCO, 2003

8. A. Mortazavi, A. Shaukat, E. Othman, J. Kepner, **M. Fakh**, D. Walsh, J. Smith, M. Javle; Roswell Park Cancer Institute, Buffalo, NY. Role of annual computerized tomographic scans of the abdomen and pelvis (CT) for post-operative surveillance of patients (pts) with stage 2 and 3 colorectal cancer (CRC-2-3). # 1470, PRO ASCO 2003
9. K. M. Qureshi, C. Leichman, J. Berdzik, T. O'Connor, M. Muffley, **M. Fakh**, P. Smith, M. Melnyk, M. Javle; Roswell Park Cancer Institute, Buffalo, NY; Comprehensive Cancer Ctr of the Desert, Palm Springs, CA. Incidence of hypersensitivity reactions to oxaliplatin (OXP) at Roswell Park Cancer Institute (RPCI) and protocol for desensitization. # 3173, PRO ASCO 2003
10. D. El Hajjar, M. Javle, D. Lawrence, N. Khoudoud, **M. Fakh**, A. Rajput, K. Donthireddy, J. Groth, J. Geradts; Roswell Park Cancer Institute, Buffalo, NY. Cyclooxygenase-2 (COX- 2) expression before and after chemoradiotherapy in rectal cancer. # 1516, PRO ASCO 2003
11. M. Melnyk, R. Yallamanchalli, D. Driscoll, B. Kuvshinoff, **M. Fakh**, H. Nava, M. Javle; Roswell Park Cancer Institute, Buffalo, NY. Metastatic pancreatic cancer: A single institution experience with gemcitabine in combination with capecitabine. # 1412, PRO ASCO 2003
12. **Fakh MG**, Zamboni W, Ramnath N, Javle MM, Schwarz JK, French RE, Regal L, Ramanathan RK, Gorenflo RK, Creaven PJ. A Phase I and pharmacokinetic (PK) study of Docetaxel (D), Cisplatin (P), and daily Capecitabine (C) (DPC) in patients with advanced solid tumors. # 448, PRO ASCO 23:2004
13. Y. Rustum, S. Cao, F. Durrani, **M. Fakh**. Se-(methyl)selenocysteine (MSC) potentiates the antitumor activity of irinotecan against human tumor xenografts and protects against drug induced toxicity. #2068, PRO ASCO 2004
14. G. S. Chatta, **M. Fakh**, S. Ramalingam, C. P. Belani, R. K. Ramanathan, W. Zamboni, D. Friedland, D. Lis, S. Tutchko, M. Egorin. Phase I pharmacokinetic (PK) study of daily imatinib in combination with docetaxel for patients with advanced solid tumors. #2047, ASCO 2004
15. E. C. McCarron, J. Gibbs, **M. Fakh**, H. R. Nava, A. Rajput. Duodenal adenocarcinoma: Vague complaints, delayed diagnosis, and poor outcome. #171 ASCO 2004
16. S. Ailawadhi, A. Rajput, G. Y. Yang, J. Smith, A. Sunga, **M. G. Fakh**. Carcinoembryonic Antigen (CEA) Surge in Patients with Metastatic Colorectal Cancer Receiving Systemic Chemotherapy. #252, ASCO 2005
17. R. V. Iyer, J. Gibbs, B. Kuvshinoff, **M. Fakh**, N. Soehnlein, D. Lawrence, J. Kepner, M. M. Javle. A phase II study of Gemcitabine (G) and Capecitabine (C) in advanced cholangiocarcinoma (CC) and gallbladder carcinoma (GBC). #139, ASCO 2005
18. **Fakh MG**, Rajput A, Smith JL, Soehnlein NA, Flaherty L, Yang GY. A Phase I Study of Weekly Oxaliplatin and Daily Capecitabine and Radiation Therapy (RT) in Locally Advanced Rectal Cancer (LARC). Poster Presentation, GI ASCO, Hollywood FL, January 27 to 29, 2005

19. **Fakih MG**, Johnson CS, Muindi JR, Black JD, Creaven PJ, Brattain MG, Kepner JL, French RA, Trump DL. A phase I and pharmacokinetic (PK) study of intravenous (IV) calcitriol and gefitinib assessing EGFR pharmacodynamic (PD) interactions through serial skin biopsies. #3995, AACR 2005
20. **Fakih MG**, Rajput G, Yang Y, Pendyala L, Toth D, Lawrence D, Smith JL, Soehnlein NA, Flaherty L, Rustum YM. A Phase I and biological correlates study of capecitabine (CAP) + oxaliplatin (OX) + radiation therapy (RT) in locally advanced rectal cancer (LARC). #3633, AACR 2005
21. Rustum Y, Pendyala L, Creaven PJ, Smith P, Azrak R, Cao S, Durrani F, Diane NC, **Fakih MG**. A phase I and pharmacokinetic (PK) study of high dose selenomethionine (SLM) in combination with irinotecan (IRI) in patients with advanced solid tumors. #2080 PRO ASCO 2005
22. Reddy NM, Zamboni WC, Creaven PJ, Ramnath N, Javle MM, Strychor S, Repinski TV, Zamboni BA, Schwarz JK, French RA, **Fakih MG**. A phase I and pharmacokinetic (PK) study of weekly docetaxel (D), cisplatin (P), and daily capecitabine (C) (DPC) in patients with advanced solid tumors. #2047, PRO ASCO 2005
23. Sunga AY, Ailawadhi S, Yang GY, Rajput A, Smith JL, **Fakih MG**. Carcinoembryonic antigen surge in patients with Metastatic colorectal cancer receiving systemic chemotherapy. #3615, PRO ASCO 2005
24. **M. G. Fakih**, L. Pendyala, K. Toth, P. Creaven, N. Soehnlein, A. Litwin, D. Trump. A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in patients with advanced colorectal cancer (CRC). #3592, PRO ASCO 2006
25. J. Yu, N. M. Reddy, A. Rajput, J. Smith, G. Yang, **M. Fakih**. Outcomes and toxicities among octogenarians and nonagenarians with colorectal cancer (crc) treated with chemotherapy or concurrent chemoradiation - a single institution study. #13514, PRO ASCO 2006
26. A. U. Pande, J. C. Lombardo, **M. Fakih**, M. K. Wong, R. V. Iyer, B. W. Kuvshinoff, M. M. Javle. Bevacizumab (BV) induced hypertension (HT): a manageable toxicity. #13539, PRO ASCO 2006
27. D. Trump, M. Javle, J. Muindi, L. Pendyala, W. Yu, N. Ramnath, M. Ross, **M. Fakih**, R. Iyer, C. Johnson. Phase I, pharmacokinetic (PK), pharmacodynamic study of paricalcitol [19-nor-1 alpha, 25-(OH)₂ D₂] in combination with gemcitabine [2',2' difluorodeoxycytidine] in patients with advanced malignancies. #12010, PRO ASCO 2006
28. N. M. Reddy, J. Yu, G. Yang, A. Rajput, J. Smith, **M. G. Fakih**. Outcomes and toxicities among octogenarians and nonagenarians with colorectal cancer (CRC) treated with chemotherapy or concurrent chemoradiation: A single institution study. #358, ASCO 2006

29. K. Donthireddy, L. Huffman, A. Sandecki, **M. G. Fakh**. Phase I study of oxaliplatin (OX), capecitabine (CAP), and gefitinib (G) in the treatment of metastatic colorectal cancer (MCRC). #240, ASCO 2006
30. **Fakh MG**, Pendyala L, Creave PJ, Smith P, Ross ME, Rustum Y. A phase I dose escalation study of selenomethionine (SLM) in combination with fixed dose irinotecan (CPT-11) in patients with advanced solid tumors. Poster presentation at the 97th AACR Annual Meeting in Washington DC, April 1 – 5, 2006.
31. **Fakh M**, Johnson C, Muindi J, Black J, Creaven P, Trump D. A phase I and pharmacokinetic study of intravenous (IV) Calcitriol and gefitinib with refractory solid tumors. Poster presentation at the 13th Workshop on Vitamin D in Victoria British Columbia, April 7 – 12, 2006.
32. Y. Rustum, L. Pendyala, P. Creaven, M. Ross, W. Brady, V. Badmaev, J. Prey, **M. G. Fakh**. A phase I dose escalation study of selenomethionine (SLM) in combination with fixed dose irinotecan (Iri) in patients with solid tumors. Poster presentation at ASCO, Orlando, Florida, January 19 – 21, 2007.
33. A. Sunga, H. Iwenofu, **M. G. Fakh**, L. Tian, D. Trump, C. Johnson, C. Levea. Differential nuclear expression of vitamin D receptor (VDR) in normal colonic mucosa, tubular adenoma, and invasive adenocarcinoma. #247, Poster presentation at ASCO, Orlando, Florida, January 19 – 21, 2007.
34. **M. G. Fakh**, M. E. Ross, P. Starostik. Increased frequency of UGT1A1 (7/7) in patients experiencing severe irinotecan-induced toxicities. #382, Poster presentation at ASCO, Orlando, Florida, January 19 – 21, 2007.
35. A. S. Bir, J. Lombardo, W. Tan, G. E. Wilding, R. Iyer, **M. G. Fakh**. Retrospective study of patients with metastatic colorectal cancer (MCRC) treated with first-line FOLFOX and bevacizumab. #445, Poster presentation at ASCO, Orlando, Florida, January 19 – 21, 2007.
36. B. Gupta, S. Abdal Raheem, W. Tan, G. E. Wilding, J. Smith, G. Yang, A. Rajput, K. Bullard Dunn, **M. G. Fakh**. Complications and effectiveness of combination chemotherapy in metastatic colorectal cancer with unresected primary (MCRC-UP). #309, Poster presentation at ASCO, Orlando, Florida, January 19 – 21, 2007.
37. S. Maddipatla, W. Tan, G. E. Wilding, D. Trump, A. Sunga, C. Johnson, J. Muindi, M. Reid, **M. G. Fakh**. Vitamin D status in patients with colorectal cancer. #260, Poster presentation at ASCO, Orlando, Florida, January 19 – 21, 2007.
38. M Vora, **M Fakh**, K Bullard Dunn, M Schiff, A Rajput, J Smith, H Nava, A Sunga Post-resection Endoscopic Surveillance among Colorectal Cancer Patients. Digestive Diseases Week, Baltimore, Maryland, 2007
39. AK Raman, JC Lombardo, R Chandrasekhar, **MG Fakh**. Bevacizumab (BV) related adverse events among various age groups of elderly patients with advanced colorectal cancer. ASCO Abstract 14546, 2007

40. Y Rustum, L Pendyala, P Creaven, M Ross, W Brady, V Badmaev, J Prey, **MG Fakh**. A phase I dose escalation study of selenomethionine (SLM) in combination with fixed dose irinotecan (Iri) in patients with solid tumors. ASCO Abstract 2574, 2007
41. **MG Fakh**, L Pendyala, P Smith, P Creaven, K Toth, J Zwiebel, S Frankel, A Litwin, L Huffman, M. Egorin. A phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in patients with advanced colorectal cancer (CRC). ASCO Abstract 4088, 2007
42. S Abdal Raheem, B Gupta, W Tan, G Wilding, J Smith, G Yang, A Rajput, K Bullard Dunn, **MG Fakh**. Complications and effectiveness of combination chemotherapy in metastatic colorectal cancer (MCRC) with unresected primary (UP). ASCO Abstract 14537, 2007
43. R Gottlieb, AM Litwin, TL Mashtare, G Wilding, CL Raczky, J Taylor, **MG Fakh**, B Gupta. Does qualitative radiologic assessment of tumor response measure up to traditional quantitative scoring methods? ASCO Abstract 17034, 2007
44. A. A. Puthillath, T. Mashtare, G. Wilding, M. Ross, M. **G. Fakh**. A phase II study of first-line biweekly regimen of capecitabine (CAP) and bevacizumab (BV) in elderly patients with metastatic colorectal cancer. 2008 Gastrointestinal Cancers Symposium - Category: Colon and Rectum - Multidisciplinary Treatment. Abstract - No. 511
45. A. A. Puthillath, P. Starostik, **M. G. Fakh**. Case control study of UGT1A1 polymorphism among patients with and without irinotecan-induced grade(G) 3-4 hematological and gastrointestinal toxicity. 2008 Gastrointestinal Cancers Symposium - Category: Colon and Rectum - Abstract - No. 295
46. J. Lombardo, **M. Fakh**. Same-day administration of pegfilgrastim with FOLFOX plus or minus bevacizumab in colorectal cancer patients. 2008 Gastrointestinal Cancers Symposium - Category: Colon and Rectum - Multidisciplinary Treatment. Abstract - No. 505
47. **M. G. Fakh**, A. Rajput, K. BullardDunn, G. Y. Yang, L. Pendyala, K. Toth, C. Andrews, Y. Rustum, M. Ross, Y. Park. A phase II neoadjuvant study of capecitabine plus oxaliplatin and radiation therapy in stage II-III rectal cancer: Efficacy results and identification of Prx-1 as a new marker of response. 2008 Gastrointestinal Cancers Symposium - Category: Colon and Rectum - Translational research - Abstract - No. 416
48. A. Y. Sunga, D. Trump, C. Johnson, L. Tian, B. Hollis, J. Muindi, K. Romano, **M. Fakh**. Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. 2008 Gastrointestinal Cancers Symposium - Category: Colon and Rectum - Prevention, diagnosis, and screening. Abstract - No. 297
49. GY Yang, KS Parikh, L Flaherty, R Chandrasekhar, G Wilding, RC Russo, **M Fakh**, BW Kuvshinoff, JF Gibbs, M Javle. Renal Function after Radiotherapy to the Abdomen. 2008 Sept, ASTRO Annual Meeting, Boston. Abstract – No. 588.
50. LK Dad, L Flaherty, LD Hales, **M Fakh**, KM Buffard-Dunn, A Rajput, JL Smith, JM Martin, W Jaggernauth, GY Yang. Concurrent Chemotherapy and Intensity-Modulated Radiation Therapy (IMRT) for Anal Cancer: Acute Morbidity and Dosimetric

Profile. Radiological Society of North America (RSNA) Annual Meeting November 30-December 5, 2008, Chicago. Abstract

51. R. Angitapalli, P. Kumar, A. Litwin, E. Nasser, J. Lombardo, T. Mashtare, G. E. Wilding, **M. Fakh**. Increase in splenic volume suggesting unrecognized portal hypertension resulting from adjuvant FOLFOX chemotherapy in colorectal cancer (CRC). *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 15028)
52. R. K. Ramanathan, **M. Fakh**, S. S. Krishnamurthi, S. Lancaster, R. A. Pinkerton, T. L. Crandall, A. Schmotzer, N. Bahary, A. A. Khorana, B. C. Lembersky. Phase II study of irinotecan (I) and cetuximab (C) on an every 2 week schedule, as second line therapy in patients (pts) with advanced colo-rectal cancer (CRC). *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 15050)
53. A. Fora, G. Yang, K. BullardDunn, A. Rajput, J. Smith, **M. Fakh**. Chemoradiation in elderly patients with rectal cancer. 2009 Gastrointestinal Cancer Symposium; abstr 434
54. A. Patel, A. Puthillath, G. Yang, A. Rajput, K. Bullard Dunn, J. Smith, **M. G. Fakh**. Pathological response and toxicities with capecitabine oxaliplatin (CAPOX) plus radiation versus fluoropyrimidine plus radiation in the neoadjuvant treatment of rectal cancer. 2009 Gastrointestinal Cancer Symposium; abstr 479
55. A. A. Puthillath, C. Andrews, D. Trump, A. Bir, K. Romano, M. Wisniewski, **M. G. Fakh**. Serological response to influenza vaccine in colorectal cancer (CRC) patients. Gastrointestinal Cancer Symposium; abstr 307
56. R. K. Sahai, K. Bullard Dunn, **M. G. Fakh**, G. Y. Yang, A. Rajput. Surgical outcome following neoadjuvant therapy for rectal cancer. Gastrointestinal Cancer Symposium; abstr 498
57. **M. G. Fakh**, C. Andrews, A. Sunga, J. McMahon, A. Fora, K. Romano, M. Wisniewski, J. Muindi A prospective high-dose cholecalciferol supplementation study in patients with colorectal cancer: Evidence of chemotherapy-vitamin D response interaction. Gastrointestinal Cancer Symposium; abstr 310
58. **M. G. Fakh**, L. Pendyala, M. J. Egorin, G. Fetterly, I. Espinoza-Delgado, M. Ross, J. Phelan, Z. Kramer, B. Yirinec, R. Diasio. A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors. American Society of Clinical Oncology 2009, abstr 4083
59. N. Sharma, I. R. Tamaskar, M. Saifo, T. Mashtare, **M. Fakh**. KRAS status and response to first-line FOLFOX chemotherapy in patients with metastatic colorectal cancer (mCRC). Gastrointestinal Cancer Symposium 2010, abstr 378
60. **M. Fakh**, M. J. Egorin, G. J. Fetterly, J. Muindi, I. J. Espinoza-Delgado, J. T. Phelan, Z. B. Kramer, B. Yirinec, R. B. Diasio. A phase I study of QD and BID vorinostat x 3 days and sFULV2 in refractory colorectal cancer and other solid tumors. Gastrointestinal Cancer Symposium 2010, abstr 334.
61. R. V. Iyer, N. I. Khushalani, W. Tan, A. Litwin, P. Starostik, C. Levea, C. Tucker, W. Ma, **M. Fakh**, A. A. Adjei. A phase II study of erlotinib in patients (pts) with advanced

pancreatic cancer (APC) who are refractory to gemcitabine (G). Gastrointestinal Cancer Symposium 2010, abstr 258

62. **M. Fakh**, J. Muindi, J. McMahon, G. Wilding, K. Romano, M. Wisniewski, M. Egorin. A phase II study of two dose levels of vorinostat in combination with fluorouracil and leucovorin in fluoropyrimidine-refractory colorectal cancer patients. ESMO 2010, abstract 618P
63. A. Patta, **M. Fakh**. Cisplatin and etoposide in the management of metastatic neuroendocrine tumors of the colon and rectum. NANETS Symposium 2010
64. Patta AM, McMahon JA, Samborski C, **Fakh MG**. A phase II trial of high-dose cetuximab (cmab) plus irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (MCRC) who progressed on standard-dose cmab plus irinotecan. J Clin Oncol 29: 2011 suppl 4; abstr 598
65. Ahmad Ali Fora, Jeanne A McMahon, Greg Wilding, Adrienne E. Groman, Wen Wee Ma, Karen S. Romano, **Marwan Fakh**. A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS-wild type tumors who progressed on prior standard dose cetuximab and irinotecan. J Clin Oncol 30, 2012 suppl; abstr 3582
66. Vincent M. Chung, Nicola Hardwick, Joshual D.I. Ellenhorn, Jonathan R. Espenschied, Dean Lim, Peiguo Chu, Dajun Qian, Joseph Kim, Joseph Chao, **Marwan Fakh**, Yun Yen, Don J. Diamond. A phase I study of an MVA vaccine targeting p53 in cancer. J Clin Oncol 31, 2013 suppl: abstr 3089
67. Vincent M. Chung, Paul Henry Frankel, Dean Lim, Joseph Chao, Christina Haeyong Yeon, Lucille A. Leong, Joseph Kim, Eloise Luevanos, Carol Rose, **Marwan Fakh**. A phase 1b trial of mFOLFOX6 and everolimus (NSC-733504) in patients with metastatic gastroesophageal adenocarcinoma (NCT01231399) J Clin Oncol 32, 2014 suppl; abstr e 15007
68. Jerome G. Kim, Chie Akiba, Dale Mitani, David D. Smith, Matthew J. Loscalzo, Stephen J. Forman, Marianna Koczywas, Sumanta Kumar Pal, Vincent M. Chung, Nitya Nathwani, **Marwan Fakh**, Leslie Popplewell, Betty R. Ferrell, Vani Katheria, Arti Hurria. Feasibility of administering a geriatric assessment to older adults with cancer using web-based and touchscreen platforms. J Clin Oncol 33, 2015 suppl; abstr 9536
69. Ding Wang, Manish R. Patel, Craig Lockhart, **Marwan Fakh**, Anthony Olzsanski, Rupal Patel, Peter Brown, Jennifer W Oliver, and Pratik Multani. RDX-105-01: An ongoing phase 1 study of RDX-105, an oral RET, BRAF and EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic cancers. 2015 EORTC-NCI-AACR
70. May Thet Cho, Jonathan Kessler, John Park, Gagandeep Singh, Yi-Jen Chen, Philip HG Ituarte, **Marwan Fakh**. A single institute retrospective trial of concurrent chemotherapy with SIR-Sphere versus SIR-Sphere alone in patients with chemotherapy-resistant colorectal cancer liver metastases. J Clin Oncol 34, 2016 (suppl 4S; abstr 770)

71. May Thet Cho, Leanne Goldstein, Chie Akiba, S. Cecilia Lau, Milhan Telatar, Michelle Afkhami, Stephen Sentovich, Kurt Melstrom, Dean Lim, Joseph Chao, Vincent M. Chung, **Marwan Fakh**. RAS mutational status and CEA production at initial presentation in metastatic colorectal cancer. J Clin Oncol 34, 2016 (suppl 4S; abstr 542)
72. May Thet Cho, Dean Lim, Timothy W. Synold, Paul Henry Frankel, Lucille A. Leong, Joseph Chao, Vincent M. Chung, Yuan Chen, Stephen Sentovich, Eloise Luevanos, **Marwan Fakh**. A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer. J Clin Oncol 34, 2016 (suppl 4S; abstr 679)
73. Joseph Chao, James Lin, Paul Henry Frankel, Andrew J. Clark, Devin T. Wiley, Edward Graeme Garmey, **Marwan Fakh**, Dean Lim, Vincent M. Chung, Eloise Luevanos, Scott Eliasof, Mark E. Davis, Yun Yen. Pilot trial of CRLX101 in patients (pts) with advanced, chemotherapy-refractory gastroesophageal cancer (GEC). J Clin Oncol 34, 2016 (suppl 4S; abstr 44)
74. Wen Wee Ma, Wasif M. Saif, Bassel F. El-Rayes, **Marwan Fakh**, Thomas H. Cartwright, James Posey, Reid von Borstel, Michael K. Bamat. Clinical trial experience with uridine triacetate for 5-fluorouracil toxicity. J Clin Oncol 34, 2016 (suppl 4S; abstr 655)
75. May Thet Cho, Dean Lim, Timothy W. Synold, Paul Henry Frankel, Lucille A. Leong, Joseph Chao, Vincent M. Chung, Yuan Chen, Stephen Sentovich, Eloise Luevanos, **Marwan Fakh**. A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer. J Clin Oncol 34, 2016 (suppl; abstr 2544)
76. Johanna C. Bendell, **Marwan Fakh**, Jeffrey R. Infante, David Lawrence Bajor, Mihaela C. Cristea, Thomas Tremblay, Ovidiu C. Trifan, Robert H. Vonderheide. Phase 1 study to evaluate the safety and tolerability of the CD40 agonistic monoclonal antibody APX005M in subjects with solid tumors. J Clin Oncol 34, 2016 (suppl; abstr TPS3110)
77. Kanwal Pratap Singh Raghav, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Bryan K. Kee, Andrea Muranyi, Shalini Singh, Mark Routbort, Ken Chen, Kenna Rael Shaw, Kandavel Shanmugam, Dipen M. Maru, **Marwan Fakh**, Scott Kopetz. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J Clin Oncol 34, 2016 (suppl; abstr 3517)
78. Manish R. Patel, **Marwan Fakh**, Anthony J. Olszanski, Albert C. Lockhart, Alexander E. Drilon, Siqing Fu, Lyudmila Bazhenova, Rupal Patel, Jennifer W. Oliver, Pratik S. Multani, Ding Wang. A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors. J Clin Oncol 34, 2016 (suppl; abstr 2574)
79. Jun Gong, Marvin Sy, **Marwan Fakh**. Tumor mutational burden of microsatellite stable metastatic colorectal tumors by patient factors and KRAS, BRAF, and PIK3CA mutation status. J Clin Oncol 35, 2017 (suppl 4S; abstract 627)

80. Patrick McKay Boland, **Marwan Fakh**, Kristopher Attwood, Melissa Robins, Renuka V. Iyer, Wen Wee Ma. A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer. J Clin Oncol 35, 2017 (suppl 4S; abstract 759)
81. Bruce A. Bach, Alexandra Christodouloupoulou, Andrew Klink, Guy Hechmati, Urvi Mujumdar, Bruce A. Feinberg, **Marwan Fakh**. Impact of RAS testing on treatment duration among patients with metastatic colorectal cancer (mCRC). J Clin Oncol 35, 2017 (suppl 4S; abstract 773)
82. Bruce A. Bach, Alexandra Christodouloupoulou, Andrew Klink, Guy Hechmati, Urvi Mujumdar, Bruce A. Feinberg, **Marwan Fakh**. Demographic and clinical characteristics of patients with metastatic colorectal cancer (mCRC) associated with RAS testing from 129 million covered lives. J Clin Oncol 35, 2017 (suppl 4S; abstract 739)
83. Joseph Chao, Yi-Jen Chen, Paul Henry Frankel, Vincent M. Chung, Dean Lim, Daneng Li, **Marwan Fakh**, Peter P. Lee. Combining pembrolizumab and palliative radiotherapy in gastroesophageal cancer to enhance anti-tumor T-cell response and augment the abscopal effect. J Clin Oncol 35, 2017 (suppl 4S; abstract TPS220)
84. Herbert Hurwitz, Kanwal Pratap Singh Raghav, Howard A. Burris, Razelle Kurzrock, Christopher Sweeney, Funda Meric-Bernstam, Ari M. Vanderwalde, David R. Spigel, Ron Bose, **Marwan Fakh**, Charles Swanton, Shuangli Guo, Coen Bernaards, Mary Stanley Beattie, Nicolas Sommer, John D. Hainsworth. Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. J Clin Oncol 35, 2017 (suppl 4S; abstract 676)